Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CCR9 | P51686 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249197 | 0.86 | KMT2A (0.47) | CA1CA2CA7CA14L3MBTL1 | |
| SCHEMBL31236179 | 0.84 | TRPV1 (0.51) | RECQLCYP2C9CYP2C19NAMPTTRPV1 | |
| SCHEMBL20249221 | 0.82 | SMN1; SMN2 (0.43) | CYP2C9L3MBTL1SMN1; SMN2LMNAHTT | |
| SCHEMBL12040428 | 0.80 | CA2 (0.46) | CA2CCR9 | |
| SCHEMBL20249178 | 0.79 | ALDH1A1 (0.47) | CA1CA2L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL20037838 | 0.79 | RECQL (0.58) | RECQLCYP2C9CYP2C19L3MBTL1SMN1; SMN2 | |
| SCHEMBL3216761 | 0.77 | KMT2A (0.62) | CYP2C19CA1CA2L3MBTL1HTT | |
| SCHEMBL19078878 | 0.77 | GABRP (0.56) | RECQLCYP2C9CYP2C19SMN1; SMN2NAMPT | |
| SCHEMBL15498266 | 0.76 | CA2 (0.38) | CA1CA2L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL20255200 | 0.76 | NNMT (0.54) | RECQLCYP2C9CYP2C19NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | RECQL 1044/4885CYP2C9 743/4885CYP2C19 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.